weight loss, Ozempic and Dr. Christopher
Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
Criminals are targeting pharmacies and stealing weight-loss medication in a country with body image insecurities and where ...
Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...
Novo Nordisk’s blockbuster GLP-1 diabetes drug Ozempic led to improvements in some measures of alcohol use disorder in a ...
Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...
Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, ...
10don MSN
Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback